{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-24-000213","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.733991+00:00","generated_at":"2026-05-29T03:04:17.782660+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GoodRx appoints Wendy Barnes as CEO and President, effective Jan 1, 2025","bullets":["Wendy Barnes named CEO/President, succeeding interim CEO Scott Wagner; also elected Class I director.","Base salary of $825,000, target bonus 100% of salary, and a $550,000 signing bonus.","Equity grants: $9M RSU, $9M option, and $2M additional RSU, vesting over time.","Severance: 12-18 months base salary plus COBRA for 18 months, with accelerated vesting on change of control.","Barnes previously CEO of RxBenefits and President of Express Scripts; holds biochemistry degree."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-24-000213","json":"https://secwatch.observer/filing/0001809519-24-000213.json","markdown":"https://secwatch.observer/filing/0001809519-24-000213.md","text":"https://secwatch.observer/filing/0001809519-24-000213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000213/0001809519-24-000213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000213/gdrx-20241212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:04:17.782660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}